Status:
TERMINATED
Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients
Lead Sponsor:
Vanderbilt University Medical Center
Collaborating Sponsors:
National Center for Research Resources (NCRR)
National Center for Advancing Translational Sciences (NCATS)
Conditions:
Septic Shock
Sepsis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Septic shock is a condition that is marked by severe infection causing hypotension requiring vasopressors to maintain adequate perfusion to vital organs. The Surviving Sepsis campaign, an internationa...
Eligibility Criteria
Inclusion
- Adults 18 years of age or greater
- Intention to treat with vasopressor for diagnosis of septic shock
- Exclusion criteria not met
Exclusion
- Emergent indication for surgery
- Patient possesses a terminal condition for which patient or medical decision maker has decided to de-escalate medical care (patients with Do Not Resuscitate order but for whom standard care is continued will not be excluded)
- Known allergy to phenylephrine or norepinephrine
- Treated with vasopressor \>12 hours for current episode of shock
- Preference of specific vasopressor agent by patient's provider
- Pregnancy
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT02203630
Start Date
August 1 2014
End Date
January 1 2016
Last Update
June 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232